How many employees does Arcutis Biotherapeutics, Inc. have?

Arcutis Biotherapeutics, Inc. reported 354 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 25, 2026. That is up 3.5% from a year earlier.

What is Arcutis Biotherapeutics, Inc.'s revenue per employee?

Arcutis Biotherapeutics, Inc. brought in $376M of revenue in fiscal Dec 2025, which is $1.06M per employee. That ranks 32 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Arcutis Biotherapeutics, Inc. employees and revenue per employee

ARQT · Biotechnology · $3.32B market cap

Arcutis Biotherapeutics, Inc. had 354 employees at the end of fiscal Dec 2025, up 3.5% from a year earlier. Revenue for the year was $376M, up 91.3% from a year earlier, or $1.06M per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

354

+3.5% YoY

Revenue

$376M

+91.3% YoY

Revenue / employee

$1.06M

Peer median $459K

Rank in industry

32 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2022

Hover a year for the numbers.

ARQT employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	354	$376M	$1.06M	+3.5%	+91.3%
Dec 2024	342	$197M	$575K	+15.5%	+229.7%
Dec 2023	296	$59.6M	$201K	+10.4%	+1517.1%
Dec 2022	268	$3.7M	$14K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Arcutis Biotherapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
INVA Innoviva, Inc.	159	$425M	$2.67M	Hiring ahead
RIGL Rigel Pharmaceuticals, Inc.	172	$294M	$1.71M	Efficient growth
CRMD CorMedix Inc.	191	$312M	$1.63M	Efficient growth
KRYS Krystal Biotech, Inc.	295	$389M	$1.32M	Efficient growth
TARS Tarsus Pharmaceuticals, Inc.	370	$451M	$1.22M	Efficient growth
ARQT Arcutis Biotherapeutics, Inc.	354	$376M	$1.06M	Efficient growth
TVTX Travere Therapeutics, Inc.	497	$491M	$987K	Efficient growth
XERS Xeris Biopharma Holdings, Inc.	435	$292M	$671K	Efficient growth
TWST Twist Bioscience Corporation	979	$377M	$385K	Efficient growth

Every Healthcare company

Questions about Arcutis Biotherapeutics, Inc.

How many employees does Arcutis Biotherapeutics, Inc. have?: Arcutis Biotherapeutics, Inc. reported 354 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 25, 2026. That is up 3.5% from a year earlier.
What is Arcutis Biotherapeutics, Inc.'s revenue per employee?: Arcutis Biotherapeutics, Inc. brought in $376M of revenue in fiscal Dec 2025, which is $1.06M per employee. That ranks 32 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare ARQT with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Arcutis Biotherapeutics, Inc.'s annual reports (Form 10-K), latest filed February 25, 2026. This is data, not a recommendation to buy or sell ARQT.